Biliary atresia is a rare condition which majorly occurs in infants. In this condition, the bile ducts that transport bile from the liver to the gall bladder are blocked. The symptoms of this disease appear about two to eight weeks after birth. Symptoms of the biliary atresia include jaundice, pale colored stools, slow or no weight gain, dark urine, and an enlarged spleen. Once biliary atresia is suspected, a surgery called Kasai portoenterostomy needs to be performed, as early operation is more likely to be successful. If the Kasai operation fails, liver transplantation may be needed.
The global biliary atresia treatment market is estimated to be valued at US$ 910.7 million in 2021 and is expected to exhibit a CAGR of 7.7% during the forecast period (2021-2028).
Figure 1. Global Biliary Atresia Treatment Market Share (%) in Terms of Value, by Disease Type, 2021
The increasing prevalence of biliary atresia and its surgery is expected to drive the market growth during the forecast period.
The increasing incidence of biliary atresia and its surgery is expected to drive the market growth during the forecast period. For instance, according to an article published by Research Gate in March 2016, babies born with biliary atresia during 1997 to 2010 were identified from the Taiwan National Health Insurance Research Database. Moreover, among 513 total biliary atresia cases, about 457 (89%) cases underwent the surgery (Kasai procedure).
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 910.7 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 7.7% | 2028 Value Projection: | US$ 1,527.9 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Biliary Atresia Treatment Market Share (%), by Treatment Type, 2021
Increasing advancements in laboratory screening and diagnosis of biliary atresia is expected to drive the market growth during the forecast period.
The increasing advancements in laboratory screening and diagnosis of biliary atresia by researchers and key players are expected to drive the biliary atresia treatment market growth during the forecast period. For instance, according to an article published in the journal ‘Digestive Medical Research’ in September 2021, recent advancements in non-invasive molecular markers, such as gamma-glutamyl transpeptidase (GGT), matrix metalloproteinase-7 (MMP7), interleukin-33 (IL-33), and stool proteomics showed promising results as effective diagnostic markers in biliary atresia.
Global Biliary Atresia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Due to the COVID-19 pandemic, pediatric liver research has faced a lot of challenges. The most impacted have been clinical research studies focusing on rare diseases like biliary atresia (BA), which is the most common indication for liver transplantation.
Biliary atresia studies done under the ‘The Childhood Liver Disease Research Network’ (ChiLDReN), an NIH-funded consortium and biorepository, has been largely interrupted during this COVID-19 pandemic, as there has been no new sample collection. Due to the failure to capture new cases of BA, the timeline of research progress will certainly be prolonged. Moreover, the diagnosis of BA has been delayed, as parents are scared of bringing their infants to their pediatrician’s hospital during this period for BA diagnosis.
As several pediatric liver diseases fall under the category of rare diseases, the unstable economic times and greatest impact of this pandemic on funding of pediatric liver research may be seen.
Global Biliary Atresia Treatment Market: Restraint
The major factors that hinder the growth of the global biliary atresia treatment market include safety concerns related to the drug, higher cost involved in the treatment, limited treatment options, and lack of skilled professional in some developing countries like India, Kenya and others.
Key Players
Major players operating in the global biliary atresia treatment market include AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals
Biliary atresia is a disease that affects infants. In this disease, the bile ducts are inflamed and blocked right after the birth. Bile is a digestive fluid that is produced and released by the liver. It travels to the small intestine through the bile ducts, where it helps in digesting fats. As the bile ducts are blocked, bile remains in the liver, where it starts to destroy liver cells rapidly and cause cirrhosis, or scarring of the liver. Reason that causes the inflammation of the ducts is not known, but it may be due to infections, toxins, immune problems. The first sign or symptom of biliary atresia is jaundice. Other symptoms include dark brown urine, difficulty in gaining weight, pale colored stools, and enlarged spleen.
In maximum cases, biliary atresia manifests several weeks to months after birth, probably after inflammation and scarring of the extrahepatic (and occasionally intrahepatic) bile ducts. It is rarely present in premature infants or in neonates at birth (or is unrecognized in neonates). Biliary atresia needs treatment by liver specialists and surgeons. Babies with blocked bile ducts require a surgery, which is called the Kasai procedure. This allows bile to drain directly from the liver into the small intestine. At the start of the surgery, the doctor will perform a cholangiogram to check if bile ducts are blocked. If they’re not blocked, the baby won’t require the procedure. Prophylactic antibiotics are often prescribed for a year postoperatively in order to prevent ascending cholangitis. Drugs that increase bile production (choleretic agents), consisting of ursodiol about are frequently used postoperatively. Nutritional therapy including supplemental fat-soluble vitamins is essential to ensure adequate intake to support growth. Even with optimal therapy, about 50% of babies develop cirrhosis and require liver transplantation.
Market Dynamics
The need to develop a safe and effective drug and the ongoing clinical trials for biliary atresia are expected to drive the global biliary atresia treatment market growth over the forecast period. For instance, as of October 2021, pentoxifylline (PTX), a methylxanthine derivative, is under phase II of clinical trials. The trial's aim is to determine if PTX has sufficient biological activity against biliary atresia to warrant further study. PTX will be administered orally for 90 days as an adjunct to standard therapy, i.e., the Kasai procedure, if applicable.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients